Xenon Pharmaceuticals Inc.
We are a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. We are advancing a novel product pipeline of neurology-focused therapies to address areas of high unmet medical need, with a focus on epilepsy.
A significant focus of our discovery efforts has been on human channelopathies, enabling us to develop strong capabilities in small molecule ion channel drug discovery. Our ion channel discovery capability is founded upon our understanding of the genetics of channelopathies combined with our proprietary biology and medicinal chemistry assets and know-how.
While the pharmaceutical industry has shown significant interest in channelopathies, a general inability to target ion channels selectively with a pharmaceutical agent has been a limitation to the development of more effective or safer therapeutics. We believe we have developed a core competence in identifying and developing selective small-molecule ion channel modulators, and we believe we can use this know-how to develop a pipeline of novel ion channel inhibitors for diseases in areas of high unmet medical need. In addition, we have complemented our internal discovery capabilities by identifying external product candidates that target ion channels in the CNS for the treatment of neurological conditions.
- Cellular Medicine
- Disease Prevention
- Drug Delivery
- Drug Discovery
- Neurological Diseases
- Product Development
We are working On:
Our “Xenon CARES” values are woven into all that we do, and we are united by a common mission to deliver innovative medicines to improve the health of patients with neurological diseases such as epilepsy. The products within our novel proprietary pipeline – including XEN496, XEN1101 and XEN007 – are aimed at treating neurological disorders, with a particular focus on epilepsy. We intend to pursue a variety of development strategies, such as those focused on using a “precision medicine” approach to address rare pediatric disorders, including KCNQ2 epilepsy, as well as those targeting broader patient populations, such as adult patients with focal epilepsy. We also have promising partnered products within our pipeline, such as NBI-921352 with Neurocrine Biosciences and FX301 with Flexion Therapeutics.
We are looking For:
We are a collaborative, ambitious, and driven team with a common mission to deliver innovative medicines to improve the health of patients. And, as a premier neuroscience company, we are committed to enhancing the lives of our employees too. This is an exciting time at Xenon. As our pipeline products advance into later stages of clinical development, we are growing across the organization. We are proud of the talent we have assembled, and we continue to look for smart and determined individuals who thrive in a fast-paced and dynamic work environment to join our team during this transformative time. Check out our current opportunities at: https://can59.dayforcehcm.com/CandidatePortal/en-us/xenon